Drug · DIN 02533448
ULTOMIRIS
SINGLE-USE VIAL
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since April 19, 2023; first marketed April 19, 2023.
- Drug Identification Number (DIN)
- 02533448
- Company (DIN owner)
- Alexion Pharma GmbhBaar, --, Switzerland
- Schedule
- Schedule d; Prescription
- Dosage form
- Solution
- Route
- Intravenous
- Therapeutic class (ATC)
- Ravulizumab L04AJ02
- Class
- Human
- Record last updated
- August 7, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| RAVULIZUMAB | 300 MG | 3 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- December 13, 2022: NOC 29686Supplement to a New Drug Submission (SNDS) · New strength
Other DINs named ULTOMIRIS
- DIN 02533456 · Marketed
- DIN 02491559 · Cancelled Post Market